Download PDF
Exp Clin Endocrinol Diabetes 2014; 122(09): 510-516
DOI: 10.1055/s-0034-1375675
Article
© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Costs of Diabetes Mellitus (CoDiM) in Germany, Direct Per-capita Costs of Managing Hyperglycaemia and Diabetes Complications in 2010 Compared to 2001

I. Köster
1   PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne, Germany
,
E. Huppertz
2   Niedererbach, Germany
,
H. Hauner
3   Else Kröner-Fresenius-Centre for Nutritional Medicine, Klinikum rechts der Isar, Technical University Munich, Germany
,
I. Schubert
1   PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne, Germany
› Author Affiliations
Further Information

Publication History

received 10 October 2013
first decision 20 April 2014

accepted 29 April 2014

Publication Date:
11 June 2014 (online)

Also available at
    Permissions and Reprints

Abstract

Introduction: To identify direct health care costs of patients with diabetes in Germany in 2010, with focus on costs of treating hyperglycaemia and costs caused by diabetes complications, and to compare findings with results from the CoDiM study 2001.

Material and methods: The cost analysis was based on administrative data (18.75% random sample of 1.5 million insured persons). Medical costs covered by statutory health insurance and costs covered by nursing care insurance were included. Incremental differences in costs of patients with diabetes (n=30 987) and age and sex-matched subjects without a diagnosis of diabetes (controls) were estimated according to the number and type of complications. Costs were standardised to the German population.

Results: In 2010, incremental medical costs attributed to diabetes were € 2 391 (95% confidence interval: 2 257–2 524) per patient with diabetes. Of that amount, 26.5% were spent for the management of hyperglycaemia (€ 633 (622–644)) and 73.5% for the treatment of comp­lications (€ 1 758 (1 627–1 889)). Nursing care contributed incremental costs of € 289 (249–330), of which 98.8% was due to complications. From 2001 to 2010 the incremental per-capita costs for medical and nursing care decreased by 4.8% (controls: +3.9%), the per-capita costs for treating hyperglycaemia increased by 2.0% and the per-capita costs for complications decreased by 7.0%.

Conclusion: Cost for diabetes is largely caused by management of complications. It is important to prevent complications by consequent management of diabetes as well as by primary prevention of its onset.

Key words

claims data - cost analysis - health care costs - incremental costs

Supplementary Material

    The table S1 and Fig. S1 of this article can be found in internet as supple­mentary material with DOI http://dx.doi.org/10.1055/s-0034-1375675.
  • Supplementary Material
 

  • References

  • 1 International Diabetes Federation (IDF). Diabetes Atlas 2012. Available from http://www.idf.org/diabetesatlas/5e/Update2012 Accessed 14 August 2013
    PubMedGoogle Scholar
  • 2 Alhowaish AK. Economic costs of diabetes in Saudi Arabia. J Family Community Med 2013; 20: 1-7
    CrossrefPubMedGoogle Scholar
  • 3 Lopez-Bastida J, Boronat M, Moreno JO et al. Costs outcomes and challenges for diabetes care in Spain. Global Health 2013; 9: 17
    CrossrefPubMedGoogle Scholar
  • 4 Waldeyer R, Brinks R, Rathmann W et al. Projection of the burden of Type 2 diabetes mellitus in Germany: A demographic modelling approach to estimate the direct medical excess costs from 2010 to 2040. Diabet Med 2013; 30: 999-1008
    CrossrefPubMedGoogle Scholar
  • 5 Hex N, Bartlett C, Wright D et al. Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med 2012; 29: 855-862
    CrossrefPubMedGoogle Scholar
  • 6 Esteghamati A, Khalilzadeh O, Anvari M et al. The economic costs of diabetes: A population-based study in Tehran, Iran. Diabetologia 2009; 52: 1520-1527
    CrossrefPubMedGoogle Scholar
  • 7 American Diabetes Association . Economic costs of diabetes in the U.S. in 2002. Diabetes Care 2003; 26: 917-932
    CrossrefPubMedGoogle Scholar
  • 8 American Diabetes Association . Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008; 31: 596-615
    CrossrefPubMedGoogle Scholar
  • 9 American Diabetes Association . Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013; 36: 1-14
    CrossrefPubMedGoogle Scholar
  • 10 Kanavos P, Aardweg S, van den Schurer W. Diabetes expenditure, burden of disease and management in 5 EU countries. LSE Health, London School of economics. 2012 Available from http://www.lse.ac.uk/LSEHealthAndSocialCare/research/LSEHealth/ MTRG/ResearchReportOnDiabetes.aspx. Accessed 14 August 2013
    PubMedGoogle Scholar
  • 11 Pelletier EM, Smith PJ, Boye KS et al. Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: A resource for economic research. Appl Health Econ Health Policy 2008; 6: 103-112
    CrossrefPubMedGoogle Scholar
  • 12 Ferber L, von Köster I, Hauner H. Kosten der antihyperglykämischen Behandlung des Diabetes mellitus Einfluss von Lebensalter, Therapieart und Komplikationsstatus: Ergebnisse der KoDiM-Studie 2001 [Costs of the treatment of hyperglycemia in patients with diabetes mellitus. The impact of age, type of therapy and complications: Results of the German CoDiM study]. Med Klin 2006; 101: 384-393 (in German)
    CrossrefPubMedGoogle Scholar
  • 13 Ferber L, von Köster I, Hauner H. Medical costs of diabetic complications. Total costs and excess costs by age and type of the treatment. Results of the German CoDiM study. Experimental and Clinical Endocrinology & Diabetes 2007; 115: 97-104
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Köster I, von Ferber L, Ihle P et al. The cost burden of diabetes mellitus: The evidence from Germany – the CoDiM Study. Diabetologia 2006; 49: 1498-1504
    CrossrefPubMedGoogle Scholar
  • 15 Schneier B. Angewandte Kryptographie. Protokolle Algorithmen und Sourcecode. Bonn [u. a.]: Addison Wesley; 1996. (in German)
    Google Scholar
  • 16 Ihle P, Köster I, Hartholz H et al. Versichertenstichprobe AOK Hessen/KV Hessen – Konzeption und Umsetzung einer personenbezogenen Datenbasis aus der Gesetzlichen Krankenversicherung [Sample survey of persons insured in statutory health insurance institutions in Hessen – concept and realisation of person-related data base]. Gesundheitswesen 2005; 67: 638-645 (in German)
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Swart E, Ihle P, Geyer S et al. GPS – good practice secondary data analysis. Working Group for the Survey and Utilization of Secondary Data (AGENS) of the German Society for Social Medicine and Prevention (DGSMP). Gesundheitswesen 2005; 67: 416-421
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Hauner H, Köster I, von Ferber L. Prävalenz des Diabetes mellitus in Deutschland 1998–2001. Sekundärdaten einer Versichertenstichprobe der AOK Hessen/KV Hessen [Prevalence of diabetes mellitus in Germany 1998–2001]. DMW 2003; 128: 2632-2637 (in German)
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 German Institute of Medical Documentation and Information (DIMDI) . Internationale statistische Klassifikation der Krankheiten und verwandter Gesundheitsprobleme 10. Revision, German Modification [Systematic Index. International Statistical Classification of Diseases and Related Health Problems 10th Revision, German Modification]. Köln, Germany: Deutscher Ärzteverlag; 2008. (in German)
    Google Scholar
  • 20 Deutsches Institut für medizinische Dokumentation und Information (DIMDI) Hrsg 2010 Anatomisch-Therapeutisch-Chemische Klassifikation mit Tagesdosen. Amtliche Fassung des ATC-Index mit DDD-Angaben für Deutschland im Jahr 2010. Erstellt vom GKV-Arzneimittelindex im Wissenschaftlichen Institut der AOK. http:///www.dimdi.de/static/de/amg/atcddd.htm (in German)
    PubMedGoogle Scholar
  • 21 Kassenärztliche Bundesvereinigung (KBV). Einheitlicher Bewertungsmaßstab (EBM). Available from http://www.kbv.de/8170.html Accessed 14.8.2013
    PubMedGoogle Scholar
  • 22 Köster I, Huppertz E, Hauner H et al. Direct costs of Diabetes mellitus in Germany – CoDiM 2000–2007. Experimental and Clinical Endocrinology & Diabetes 2011; 119: 377-385
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 German Institute of Medical Documentation and Information (DIMDI). Operationen- und Prozedurenschlüssel (OPS). Available from http://www.dimdi.de/statis/de/klassi/ops/index.htm Accessed 14.8.2013
    PubMedGoogle Scholar
  • 24 Hauner H, Köster I, Schubert I. Trends in der Prävalenz und ambulanten Versorgung von Menschen mit Diabetes mellitus – Eine Analyse der Versichertenstichprobe AOK Hessen/KV Hessen im Zeitraum von 1998 bis 2004 [Trends in prevalence and primary care of patient with diabetes mellitus between 1998 and 2004: A study based on the Versichertenstichprobe AOK Hesse/KV Hesse]. Dtsch Arztebl 2007; 104: A279-A805 (in German)
    PubMedGoogle Scholar
  • 25 Köster I, Schubert I, Huppertz E. Fortschreibung der KoDiM-Studie: Kosten des Diabetes mellitus 2000–2009 [Update of CoDiM study: Costs of diabetes mellitus 2000–2009]. DMW 2012; 137: 1-4 (in ­German)
    PubMedGoogle Scholar
  • 26 DESTATIS . Gesundheit – Krankheitskosten – 2002, 2004, 2006 und 2008 [Health – Health care costs 2002, 2004, 2006 und 2008]. Fachserie 12, Reihe 7.2. Wiesbaden 2010 (in German)
    PubMedGoogle Scholar
  • 27 IQWiG Cost estimation – working paper, Version 1.0. 2009. Available from https://www.iqwig.de/download/Arbeitspapier_Kostenbestimmung_v_1_0.pdf Accessed 16.8.2013
    PubMed
  • 28 DESTATIS. Verbraucherpreisindizes für Deutschland [Consumer price overall index]. Fachserie 17, Reihe 7. Wiesbaden 2013 (in German)
    PubMedGoogle Scholar
  • 29 DiCiccio TJ, Efron B. Bootstrap confidence intervals. Statistical Science 1996; 11: 189-228
    CrossrefPubMedGoogle Scholar
  • 30 The writing team for the Diabetes Control and Complication Trial/Epidemiology of Diabetes Interventions and complications (DCCT/EDIC) Research Group . Effect of intensive therapy on the microvascular complications of Type 1 diabetes mellitus. JAMA 2002; 287: 2563-2569
    CrossrefPubMedGoogle Scholar
  • 31 The Diabetes Control and Complication Trial/Epidemiology of Diabetes Interventions and complications (DCCT/EDIC) Study Research Group . Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653
    CrossrefPubMedGoogle Scholar
  • 32 Holman RR, Paul SK, Bethel A et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589
    CrossrefPubMedGoogle Scholar
  • 33 Leśniowska J, Schubert A, Wojna M et al. Costs of diabetes and its complications in Poland. Eur J Health Econ 2013; [Epub ahead of print] DOI: 10.1007/s10198-0113-0513-0.
    PubMedGoogle Scholar
  • 34 Li R, Bilik D, Brown MB et al. Medical costs associated with type 2 diabetes complications and comorbidities. Am J Manag Care 2013; 19: 421-430
    PubMedGoogle Scholar
  • 35 Kim TH, Chun KH, Kim HJ et al. Direct medical costs for patients with type 2 diabetes and related complications: A prospective cohort study based on the Korean National Diabetes Program. J Korean Med Sci 2012; 27: 876-882
    CrossrefPubMedGoogle Scholar
  • 36 Wu CX, Tan WS, Toh MP et al. Stratifying healthcare costs using the Diabetes Complication Severity Index. J Diabetes Complications 2012; 26: 107-112
    CrossrefPubMedGoogle Scholar
  • 37 Clarke PM, Glasziou P, Patel A et al. Event rates, hospital utilization, and costs associated with major complications of diabetes: A multicountry comparative analysis. PLoS Med 2010; 7: e1000236
    CrossrefPubMedGoogle Scholar
  • 38 Martin S, Schramm W, Schneider B et al. Epidemiology of complications and total treatment costs from diagnosis of type 2 diabetes in Germany (ROSSO 4). Exp Clin Endocrinol Diabetes 2007; 115: 495-502
    Article in Thieme ConnectPubMedGoogle Scholar
  • 39 Korber K, Teuner CM, Lampert T et al. Direkte Krankheitskosten von Diabetes mellitus in Deutschland: erste Abschätzung der Unterschiede zwischen Bildungsgruppen [Direct Costs of Diabetes Mellitus in Germany: First Estimation of the Differences Related to Educational Level]. Gesundheitswesen 2013; 75: 812-818 (in German)
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Bundesministerium für Gesundheit (BMG) . Daten des Gesundheitswesens 2012. Available from www.bmg.bund.de/fileadmin/dateien/Publikationen/Gesundheit/Broschueren/Daten_des_Gesundheitswesens_2013.pdf Accessed 1.10.2013
    PubMedGoogle Scholar
  • 41 Heidemann C, Du Y, Schubert I et al. Prävalenz und zeitliche Entwicklung des bekannten Diabetes mellitus. Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS 1) [Prevalence and temporal trend of known diabetes mellitus. Results of the German Health Interview and Examination Survey for Adults (DEGS 1)]. Bundesgesundheitbl 2013; 56: 668-677 (in German)
    PubMedGoogle Scholar
  • 42 Hoffmann F, Icks A. Diabetes prevalence based on health insurance claims: Large differences between companies. Diabetic Medicine 2011; 28: 919-923
    CrossrefPubMedGoogle Scholar